STOCK TITAN

[SCHEDULE 13D/A] Abivax SA American SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13D/A
Rhea-AI Filing Summary

On 07/29/2025, GeneDx Holdings Corp. (WGS) CEO & Director Katherine Stueland reported routine equity-compensation activity. She converted 3,874 RSUs into Class A common stock at $0 (Code M) and sold 2,154 shares at $105.31 in a “sell-to-cover” trade to meet tax-withholding obligations (Code S). Net of the sale, her direct stake rose to 3,440 shares.

The filing highlights a sizeable remaining incentive package: 469,835 unvested RSUs and 107,610 stock options that vest 25 % annually through April 2024 and quarterly thereafter, subject to continued service. These awards could materially increase future ownership and align management interests with shareholders, while the current sale appears administrative rather than indicative of sentiment.

Il 29/07/2025, Katherine Stueland, CEO e Direttrice di GeneDx Holdings Corp. (WGS), ha comunicato un'attività ordinaria di compensazione azionaria. Ha convertito 3.874 RSU in azioni ordinarie di Classe A a prezzo zero (Codice M) e ha venduto 2.154 azioni a 105,31 $ in un'operazione “sell-to-cover” per adempiere alle obbligazioni fiscali (Codice S). Dopo la vendita, la sua partecipazione diretta è salita a 3.440 azioni.

La comunicazione evidenzia un consistente pacchetto incentivante residuo: 469.835 RSU non maturate e 107.610 opzioni azionarie che maturano al 25% annuo fino ad aprile 2024 e trimestralmente successivamente, subordinatamente al mantenimento del servizio. Questi premi potrebbero aumentare significativamente la proprietà futura e allineare gli interessi del management con quelli degli azionisti, mentre la vendita attuale sembra di natura amministrativa piuttosto che riflettere un sentimento negativo.

El 29/07/2025, Katherine Stueland, CEO y Directora de GeneDx Holdings Corp. (WGS), informó sobre una actividad rutinaria de compensación en acciones. Ella convirtió 3,874 RSU en acciones ordinarias Clase A a $0 (Código M) y vendió 2,154 acciones a $105.31 en una operación de “sell-to-cover” para cubrir obligaciones fiscales (Código S). Tras la venta, su participación directa aumentó a 3,440 acciones.

El informe destaca un importante paquete de incentivos pendiente: 469,835 RSU no adquiridas y 107,610 opciones sobre acciones que se adquieren al 25 % anual hasta abril de 2024 y trimestralmente después, sujeto a la continuidad del servicio. Estos premios podrían incrementar significativamente la propiedad futura y alinear los intereses de la dirección con los de los accionistas, mientras que la venta actual parece administrativa más que indicativa de un sentimiento.

2025년 7월 29일, GeneDx Holdings Corp.(WGS)의 CEO 겸 이사인 캐서린 스튜엘랜드는 정기적인 주식 보상 활동을 보고했습니다. 그녀는 3,874개의 RSU를 $0(코드 M)에 클래스 A 보통주로 전환하고, 세금 원천징수 의무를 충족하기 위해 2,154주를 주당 $105.31에 판매하는 'sell-to-cover' 거래를 진행했습니다(코드 S). 판매 후 그녀의 직접 지분은 3,440주로 증가했습니다.

보고서에는 상당한 인센티브 패키지가 남아 있음을 강조합니다: 469,835개의 미확정 RSU107,610개의 주식 옵션이 2024년 4월까지 연간 25%씩, 이후 분기별로 베스팅되며 계속 근무 조건이 적용됩니다. 이 보상들은 향후 소유 지분을 크게 늘리고 경영진과 주주 간 이해관계를 일치시킬 수 있으며, 현재의 주식 매도는 감정의 표시라기보다 행정적인 성격으로 보입니다.

Le 29/07/2025, Katherine Stueland, PDG et directrice de GeneDx Holdings Corp. (WGS), a déclaré une activité courante de rémunération en actions. Elle a converti 3 874 RSU en actions ordinaires de classe A à 0 $ (Code M) et a vendu 2 154 actions à 105,31 $ dans une opération « sell-to-cover » pour couvrir les obligations fiscales (Code S). Après la vente, sa participation directe est montée à 3 440 actions.

Le dépôt souligne un important plan d’incitation restant : 469 835 RSU non acquises et 107 610 options d’achat d’actions qui acquièrent 25 % par an jusqu’en avril 2024, puis trimestriellement, sous réserve de la poursuite du service. Ces attributions pourraient augmenter significativement la détention future et aligner les intérêts de la direction avec ceux des actionnaires, tandis que la vente actuelle semble être de nature administrative plutôt qu’un signe de sentiment.

Am 29.07.2025 meldete Katherine Stueland, CEO und Direktorin von GeneDx Holdings Corp. (WGS), routinemäßige Aktienvergütungsaktivitäten. Sie wandelte 3.874 RSUs in Stammaktien der Klasse A zu 0 $ (Code M) um und verkaufte 2.154 Aktien zu 105,31 $ in einem „Sell-to-Cover“-Geschäft zur Erfüllung von Steuerabzugsverpflichtungen (Code S). Nach dem Verkauf stieg ihr direkter Anteil auf 3.440 Aktien.

Die Meldung hebt ein beträchtliches verbleibendes Anreizpaket hervor: 469.835 unverfallte RSUs und 107.610 Aktienoptionen, die jährlich zu 25 % bis April 2024 und danach vierteljährlich unter der Bedingung fortgesetzter Dienstzeit vesten. Diese Auszeichnungen könnten den zukünftigen Besitz erheblich erhöhen und die Interessen des Managements mit denen der Aktionäre in Einklang bringen, während der aktuelle Verkauf eher administrativer Natur als ein Stimmungsindikator zu sein scheint.

Positive
  • Large remaining incentive pool: 469,835 RSUs and 107,610 options keep CEO interests aligned with long-term shareholder value.
  • Sale conducted under sell-to-cover and Rule 10b5-1 framework, limiting perception of discretionary insider selling.
Negative
  • Share issuance from RSU settlement adds 3,874 new shares to the float, albeit immaterial in size.

Insights

TL;DR: CEO executes standard RSU vesting; small tax sale, large unvested equity remains—overall neutral, alignment intact.

The Form 4 shows typical compensation mechanics. The 2,154-share sale (≈$227k gross) was mandated for taxes, limiting signaling value. Importantly, Stueland retains potential exposure to >577k shares via RSUs and options, reinforcing long-term incentive alignment. The transaction has negligible dilution and no impact on earnings or guidance; therefore, market impact should be minimal.

TL;DR: Administrative trade; substantial unvested equity supports shareholder alignment—no governance red flags.

The CEO’s sale is explicitly for withholding and mirrors best-practice use of 10b5-1 safeguards. Continued large unvested holdings mitigate concerns about short-termism. No multiple filers or complex indirect ownership structures were disclosed, simplifying oversight. I view the event as routine and not materially impactful to governance risk.

Il 29/07/2025, Katherine Stueland, CEO e Direttrice di GeneDx Holdings Corp. (WGS), ha comunicato un'attività ordinaria di compensazione azionaria. Ha convertito 3.874 RSU in azioni ordinarie di Classe A a prezzo zero (Codice M) e ha venduto 2.154 azioni a 105,31 $ in un'operazione “sell-to-cover” per adempiere alle obbligazioni fiscali (Codice S). Dopo la vendita, la sua partecipazione diretta è salita a 3.440 azioni.

La comunicazione evidenzia un consistente pacchetto incentivante residuo: 469.835 RSU non maturate e 107.610 opzioni azionarie che maturano al 25% annuo fino ad aprile 2024 e trimestralmente successivamente, subordinatamente al mantenimento del servizio. Questi premi potrebbero aumentare significativamente la proprietà futura e allineare gli interessi del management con quelli degli azionisti, mentre la vendita attuale sembra di natura amministrativa piuttosto che riflettere un sentimento negativo.

El 29/07/2025, Katherine Stueland, CEO y Directora de GeneDx Holdings Corp. (WGS), informó sobre una actividad rutinaria de compensación en acciones. Ella convirtió 3,874 RSU en acciones ordinarias Clase A a $0 (Código M) y vendió 2,154 acciones a $105.31 en una operación de “sell-to-cover” para cubrir obligaciones fiscales (Código S). Tras la venta, su participación directa aumentó a 3,440 acciones.

El informe destaca un importante paquete de incentivos pendiente: 469,835 RSU no adquiridas y 107,610 opciones sobre acciones que se adquieren al 25 % anual hasta abril de 2024 y trimestralmente después, sujeto a la continuidad del servicio. Estos premios podrían incrementar significativamente la propiedad futura y alinear los intereses de la dirección con los de los accionistas, mientras que la venta actual parece administrativa más que indicativa de un sentimiento.

2025년 7월 29일, GeneDx Holdings Corp.(WGS)의 CEO 겸 이사인 캐서린 스튜엘랜드는 정기적인 주식 보상 활동을 보고했습니다. 그녀는 3,874개의 RSU를 $0(코드 M)에 클래스 A 보통주로 전환하고, 세금 원천징수 의무를 충족하기 위해 2,154주를 주당 $105.31에 판매하는 'sell-to-cover' 거래를 진행했습니다(코드 S). 판매 후 그녀의 직접 지분은 3,440주로 증가했습니다.

보고서에는 상당한 인센티브 패키지가 남아 있음을 강조합니다: 469,835개의 미확정 RSU107,610개의 주식 옵션이 2024년 4월까지 연간 25%씩, 이후 분기별로 베스팅되며 계속 근무 조건이 적용됩니다. 이 보상들은 향후 소유 지분을 크게 늘리고 경영진과 주주 간 이해관계를 일치시킬 수 있으며, 현재의 주식 매도는 감정의 표시라기보다 행정적인 성격으로 보입니다.

Le 29/07/2025, Katherine Stueland, PDG et directrice de GeneDx Holdings Corp. (WGS), a déclaré une activité courante de rémunération en actions. Elle a converti 3 874 RSU en actions ordinaires de classe A à 0 $ (Code M) et a vendu 2 154 actions à 105,31 $ dans une opération « sell-to-cover » pour couvrir les obligations fiscales (Code S). Après la vente, sa participation directe est montée à 3 440 actions.

Le dépôt souligne un important plan d’incitation restant : 469 835 RSU non acquises et 107 610 options d’achat d’actions qui acquièrent 25 % par an jusqu’en avril 2024, puis trimestriellement, sous réserve de la poursuite du service. Ces attributions pourraient augmenter significativement la détention future et aligner les intérêts de la direction avec ceux des actionnaires, tandis que la vente actuelle semble être de nature administrative plutôt qu’un signe de sentiment.

Am 29.07.2025 meldete Katherine Stueland, CEO und Direktorin von GeneDx Holdings Corp. (WGS), routinemäßige Aktienvergütungsaktivitäten. Sie wandelte 3.874 RSUs in Stammaktien der Klasse A zu 0 $ (Code M) um und verkaufte 2.154 Aktien zu 105,31 $ in einem „Sell-to-Cover“-Geschäft zur Erfüllung von Steuerabzugsverpflichtungen (Code S). Nach dem Verkauf stieg ihr direkter Anteil auf 3.440 Aktien.

Die Meldung hebt ein beträchtliches verbleibendes Anreizpaket hervor: 469.835 unverfallte RSUs und 107.610 Aktienoptionen, die jährlich zu 25 % bis April 2024 und danach vierteljährlich unter der Bedingung fortgesetzter Dienstzeit vesten. Diese Auszeichnungen könnten den zukünftigen Besitz erheblich erhöhen und die Interessen des Managements mit denen der Aktionäre in Einklang bringen, während der aktuelle Verkauf eher administrativer Natur als ein Stimmungsindikator zu sein scheint.






If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






SCHEDULE 13D




Comment for Type of Reporting Person:
Note in relation to Items 7 and 8: Sofinnova Partners SAS, a French corporation ("SP SAS"), the management company of Sofinnova Crossover I SLP ("SC"), may be deemed to have sole voting power, and Antoine Papiernik ("Papiernik"), Cedric Moreau ("Moreau"), Kinam Hong ("Hong"), Joseph Anderson ("Anderson") and Jacques Theurillat ("Theurillat"), the members of the investment committee of SC, may be deemed to have shared power to vote these shares. Note in relation to Items 9 and 10: SP SAS, the management company of SC, may be deemed to have sole power to dispose of these shares, and Papiernik, Moreau, Hong, Anderson and Theurillat, the members of the investment committee of SC, may be deemed to have shared power to dispose of these shares. Note in relation to Items 8, 10, 11 and 13: The Reporting Person beneficially owns 5,534,739 Ordinary Shares (including ordinary shares represented by American depositary shares) and has 9,599,478 voting rights related to such shares. The aggregate amount beneficially owned and percent of class reported above are based on the Reporting Person's voting rights and the 84,464,060 voting rights outstanding as of July 28, 2025.


SCHEDULE 13D




Comment for Type of Reporting Person:
Note in relation to Items 7 and 8: SP SAS, the management company of SC, may be deemed to have sole voting power, and Papiernik, Moreau, Hong, Anderson and Theurillat, the members of the investment committee of SC, may be deemed to have shared power to vote these shares. Note in relation to Items 9 and 10: SP SAS, the management company of SC, may be deemed to have sole power to dispose of these shares, and Papiernik, Moreau, Hong, Anderson and Theurillat, the members of the investment committee of SC, may be deemed to have shared power to dispose of these shares. Note in relation to Items 8, 10, 11 and 13: The Reporting Person beneficially owns 5,534,739 Ordinary Shares (including ordinary shares represented by American depositary shares) and has 9,599,478 voting rights related to such shares. The aggregate amount beneficially owned and percent of class reported above are based on the Reporting Person's voting rights and the 84,464,060 voting rights outstanding as of July 28, 2025.


SCHEDULE 13D




Comment for Type of Reporting Person:
Note to Items 5 and 6: SP SAS, the management company of SC, may be deemed to have sole voting power, and Papiernik, a member of the investment committee of SC, may be deemed to have shared power to vote these shares. Note to Items 7 and 8: SP SAS, the management company of SC, may be deemed to have sole power to dispose of these shares, and Papiernik, a member of the investment committee of SC, may be deemed to have shared power to dispose of these shares. Note in relation to Items 8, 10, 11 and 13: The Reporting Person beneficially owns 5,534,739 Ordinary Shares (including ordinary shares represented by American depositary shares) and has 9,599,478 voting rights related to such shares. The aggregate amount beneficially owned and percent of class reported above are based on the Reporting Person's voting rights and the 84,464,060 voting rights outstanding as of July 28, 2025.


SCHEDULE 13D




Comment for Type of Reporting Person:
Note to Items 5 and 6: SP SAS, the management company of SC, may be deemed to have sole voting power, and Moreau, a member of the investment committee of SC, may be deemed to have shared power to vote these shares. Note to Items 7 and 8: SP SAS, the management company of SC, may be deemed to have sole power to dispose of these shares, and Moreau, a member of the investment committee of SC, may be deemed to have shared power to dispose of these shares. Note in relation to Items 8, 10, 11 and 13: The Reporting Person beneficially owns 5,534,739 Ordinary Shares (including ordinary shares represented by American depositary shares) and has 9,599,478 voting rights related to such shares. The aggregate amount beneficially owned and percent of class reported above are based on the Reporting Person's voting rights and the 84,464,060 voting rights outstanding as of July 28, 2025.


SCHEDULE 13D




Comment for Type of Reporting Person:
Note to Items 5 and 6: SP SAS, the management company of SC, may be deemed to have sole voting power, and Hong, a member of the investment committee of SC, may be deemed to have shared power to vote these shares. Note to Items 7 and 8: SP SAS, the management company of SC, may be deemed to have sole power to dispose of these shares, and Hong, a member of the investment committee of SC, may be deemed to have shared power to dispose of these shares. Note in relation to Items 8, 10, 11 and 13: The Reporting Person beneficially owns 5,534,739 Ordinary Shares (including ordinary shares represented by American depositary shares) and has 9,599,478 voting rights related to such shares. The aggregate amount beneficially owned and percent of class reported above are based on the Reporting Person's voting rights and the 84,464,060 voting rights outstanding as of July 28, 2025.


SCHEDULE 13D




Comment for Type of Reporting Person:
Note to Items 5 and 6: SP SAS, the management company of SC, may be deemed to have sole voting power, and Anderson, a member of the investment committee of SC, may be deemed to have shared power to vote these shares. Note to Items 7 and 8: SP SAS, the management company of SC, may be deemed to have sole power to dispose of these shares, and Anderson, a member of the investment committee of SC, may be deemed to have shared power to dispose of these shares. Note in relation to Items 8, 10, 11 and 13: The Reporting Person beneficially owns 5,534,739 Ordinary Shares (including ordinary shares represented by American depositary shares) and has 9,599,478 voting rights related to such shares. The aggregate amount beneficially owned and percent of class reported above are based on the Reporting Person's voting rights and the 84,464,060 voting rights outstanding as of July 28, 2025.


SCHEDULE 13D




Comment for Type of Reporting Person:
Note to Items 5 and 6: SP SAS, the management company of SC, may be deemed to have sole voting power, and Theurillat, a member of the investment committee of SC, may be deemed to have shared power to vote these shares. Note to Items 7 and 8: SP SAS, the management company of SC, may be deemed to have sole power to dispose of these shares, and Theurillat, a member of the investment committee of SC, may be deemed to have shared power to dispose of these shares. Note in relation to Items 8, 10, 11 and 13: The Reporting Person beneficially owns 5,534,739 Ordinary Shares (including ordinary shares represented by American depositary shares) and has 9,599,478 voting rights related to such shares. The aggregate amount beneficially owned and percent of class reported above are based on the Reporting Person's voting rights and the 84,464,060 voting rights outstanding as of July 28, 2025.


SCHEDULE 13D


Sofinnova Crossover I SLP
Signature:/s/ Antoine Papiernik
Name/Title:Managing Partner
Date:07/30/2025
Sofinnova Partners SAS
Signature:/s/ Antoine Papiernik
Name/Title:Managing Partner
Date:07/30/2025
Antoine Papiernik
Signature:/s/ Antoine Papiernik
Name/Title:Antoine Papiernik
Date:07/30/2025
Cedric Moreau
Signature:/s/ Cedric Moreau
Name/Title:Cedric Moreau
Date:07/30/2025
Kinam Hong
Signature:/s/ Kinam Hong
Name/Title:Kinam Hong
Date:07/30/2025
Joseph Anderson
Signature:/s/ Joseph Anderson
Name/Title:Joseph Anderson
Date:07/30/2025
Jacques Theurillat
Signature:/s/ Jacques Theurillat
Name/Title:Jacques Theurillat
Date:07/30/2025
Abivax S.A.

NASDAQ:ABVX

ABVX Rankings

ABVX Latest News

ABVX Latest SEC Filings

ABVX Stock Data

5.32B
63.42M
47.53%
1.95%
Biotechnology
Healthcare
Link
France
Paris